Trump administration strikes policy that supporters say helped lower drug prices
The Obama administration designed certain Medicare payments to encourage price competition among biosimilar drugs. Trump's CMS will roll back that policy.
WASHINGTON — The Trump administration on Thursday boldly reversed an Obama-era policy that supporters said had helped lower prices for some costly drugs.
The policy centers on so-called biosimilar drugs, which are highly similar versions of biologic drugs manufactured in living cells or microorganisms. The Obama administration designed certain Medicare payments to encourage more price competition among those
